Expert Interview
Discussing the recent label expansion for Genentech's Alecensa (alectinib) as first adjuvant treatment for people With ALK-Positive Early-Stage Lung Cancer.
Ticker(s): RHHBYInstitution: University of Colorado
- Assistant Professor of Medicine in Oncology at University of Colorado.
- Treats over 20 patients with ALK-Positive lung cancer and leads multiple clinical trials investigating novel immunotherapy approaches for patients with lung cancer.
- Schenk Lab investigates the lung cancer tumor microenvironment as a contributor to lung cancer progression and treatment resistence.
Do you have experience prescibing Alecensa (alectinib), and can you discuss the patient feedback and clinical success thus far?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of Alecensa, what would it be and why
How does Alecensa compare to other treatment options for your patients with ALK-positive lung cancer?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
